Durvalumab

From IDWiki
  • Human IgG1k monoclonal antibody that blocks PD-L1 from interacting PD-1 and CD-80
  • Indicated for urothelial carcinoma, small cell lung cancer, non-small cell lung cancer
  • Adverse effects include
    • Cardiac: hypertension (6%), myocarditis (rare)
    • Dermatologic: rash with pruritus (22%)
    • Gastrointestinal: abdominal pain (10%), anorexia (14%), constipation (12%), diarrhea (18%), colitis (2%), nausea/vomiting (14%)
    • General: edema (8%), fatigue (24%)
    • Hematologic: immune-mediated thrombocytopenic purpura (rare)
    • Hepatobiliary: elevated liver tests (6%), hepatitis (2%), pancreatitis (rare)
    • Hypersensitivity: infusion reactions (2%)
    • Infection (26%): UTI and pneumonia most commonly
    • Metabolic: adrenal insufficiency (rare), diabetes mellitus (rare), hyperthyroidism (8%), hypophysitis (rare), hypothyroidism (12%), thyroiditis (2%)
    • MSK: pain (12%)
    • CNS: aseptic meningitis or encephalitis (rare), headache (11%), insomnia (10%)
    • Ophthalmic: uveitis (rare)
    • Renal: increased creatinine (5%)
    • Respiratory: cough or dyspnea (40%), severe cough or dyspnea (1%), dysphonia (4%), pneumonitis (3%, but up to 34% in NSCLC)